UK markets closed

Roche Holding AG (ROG.SW)

Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
252.80+2.80 (+1.12%)
At close: 05:30PM CEST
Full screen
Previous close250.00
Bid252.80 x 0
Ask252.90 x 0
Day's range250.10 - 254.10
52-week range212.90 - 277.90
Avg. volume1,384,779
Market cap203.975B
Beta (5Y monthly)0.16
PE ratio (TTM)17.67
EPS (TTM)14.31
Earnings date25 Jul 2024
Forward dividend & yield9.60 (3.80%)
Ex-dividend date14 Mar 2024
1y target est271.95
  • GlobeNewswire

    Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

    The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2The test helps differentiate a B-cell cancer from a normal, reactive immune response, providing diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is the tenth most common cancer

  • Zacks

    Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

    Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.

  • PR Newswire

    Roche receives FDA clearance on its digital pathology solution for diagnostic use

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), has received 510(k) clearance from the United States Food and Drug Administration (FDA). The system is intended to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.